Title

運用實證探討口服麩醯胺對癌症病人接受化學治療引起的周邊神經病變之成效

Translated Titles

Effect of Oral Glutamine on Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: An Evidence-Based Appraisal

DOI

10.6224/JN.201802_65(1).09

Authors

孫婉娜(Wan-Na Sun);蘇靖幃(Jing-Wei Su);申子蘋(Zih-Ping Shen);許心恬(Hsin-Tien Hsu)

Key Words

麩醯胺 ; 化學治療造成周邊神經病變 ; 實證評價 ; glutamine ; chemotherapy-induced peripheral neuropathy ; evidence-based appraisal

PublicationName

護理雜誌

Volume or Term/Year and Month of Publication

65卷1期(2018 / 02 / 01)

Page #

61 - 69

Content Language

繁體中文

Chinese Abstract

背景:化學治療造成周邊神經病變(chemotherapy-induced peripheral neuropathy, CIPN),嚴重時須減少或停止化療藥物劑量及療程。針對CIPN治療方式無明確指引,口服麩醯胺(glutamine)為方法之一,但價格高且成效及劑量不明確。目的:確認口服glutamine在CIPN成效。方法:依據PICO(population-intervention-comparison-outcome)的方式來詮釋問題,P為接受化療癌症病人;I為麩醯胺、左旋麩胺酸;C為一般照護;O為緩解、減少或改善CIPN,於華藝、Cochrane、CINAHL、PubMed資料庫檢索,藉實證手法評析三篇隨機分派臨床實驗及兩篇類實驗性研究設計,並進行成果測量統合分析。結果:有四篇研究劑量為30克/天,使用時間點為化療開始時或化療後24小時內,時間最短為四天,最長則連續一至兩個月。glutamine組與對照組在疼痛發生risk ratio = 0.26(95% CI [0.09, 0.70], Z = 2.65, p =.008),顯示glutamine組較對照組少發生疼痛且達顯著差異,而CIPN嚴重度等級、麻木感及肌肉無力在兩組則無明顯差異。從經濟效益來看,病人使用glutamine一天需額外負擔五百元費用,花費高。結論/實務應用:由於樣本數小,結果呈現疼痛有改善,但費用增加及風險危害未顯著降低,故不主動建議化療病人為預防或改善CIPN症狀而使用口服glutamine。

English Abstract

Background: Chemotherapy may induce peripheral neuropathy, which often results in the chemotherapy dose being reduced or the chemotherapy regimen being stopped. At present, there are no treatment guidelines for chemotherapy-induced peripheral neuropathy. Glutamine is one of the treatment strategies currently applied in practice. This strategy is expensive and lacks clear evidence as to its efficacy. Purpose: To evaluate the effect of oral glutamine on CIPN in cancer patients. Methods: PICO (population- intervention- comparison- outcome) was used to focus the problem: P: cancer patient; I: glutamine, L-glutamine; C: usual care; O: alleviate, reduce, improve, and prevent. Databases searched included Airiti Library, Cochrane Library, CINAHL, and PubMed. Three randomized clinical trials and two quasi-experimental designs were evaluated using evidence-based appraisal. Results: Four studies used 30 g/day of glutamine either at the beginning of chemotherapy or at 24 hours after the beginning of chemotherapy. The shortest duration for taking glutamine was four days and longest duration was two months. The incidences of CIPN-induced pain were significantly different (risk ratio = 0.26; 95% CI [0.09, 0.70], Z = 2.65, p = .008) between the intervention and control groups. The incidences of CIPN grading, numbness, and muscle weakness were not significantly different between the intervention and control groups. From an economic point of view, the clinical efficacy of taking glutamine does not justify the additional daily cost to the patient of NT$500 (about US$17). Conclusions/Implications for Practice: Because of the small sample size, minimal effects of glutamine, and no significant decrease in risk, we do not suggest routinely using oral glutamine to prevent or reduce CIPN symptoms in cancer patients.

Topic Category 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
Reference
  1. 徐書儀、呂長賢、陳淑真、簡淑慧(2015).淺談化學治療引起周邊神經性病變之護理照護.護理雜誌,62(2),84–88。[Hsu, S. Y., Lu, C. H., Chen, S. Z., & Jane, S. W. (2015). Nursing care of chemotherapy-induced peripheral neuropathy. The Journal of Nursing, 62(2), 84–88.] https://doi.org/10.6224/JN.62.2.84
    連結:
  2. 郭孟慈、許心恬(2015).化學治療引起的周邊神經病變之簡介.腫瘤護理雜誌,15(2),69–82。[Kuo, M. T., & Hsu, H. T. (2015). An introduction of chemotherapy- Induced peripheral neuropathy. The Journal of Oncology Nursing, 15(2), 69–82.] https://doi.org/10.3966/168395442015121502006
    連結:
  3. Amara, S. (2008). Oral glutamine for the prevention of chemotherapy-Induced peripheral neuropathy. Annals of Pharmacotherapy, 42(10), 1481–1485. https://doi.org/10.1345/aph.1L179
    連結:
  4. Beutheu, S., Ouelaa, W., Guérin, C., Belmonte, L., Aziz, M., Tennoune, N., ... Coëffier, M. (2014). Glutamine supplementation, but not combined glutamine and arginine supplementation, improves gut barrier function during chemotherapy-Induced intestinal mucositis in rats. Clinical Nutrition, 33(4), 694–701. https://doi.org/10.1016/j.clnu.2013.09.003
    連結:
  5. Brami, C., Bao, T., & Deng, G. (2016). Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Critical Reviews in Oncology/Hematology, 98, 325–334. https://doi.org/10.1016/j.critrevonc.2015.11.014
    連結:
  6. Gabr, A., Salem, A. A. S., Samy, H. A., Tmam, S., & Ali, A. M. (2016). N(2)-L-alanyl-L-glutamine dipeptide preventing oxaliplatin-induced neurotoxicity in colorectal cancer patients. Journal of Cancer Therapy, 7(9), 609–621. https://doi.org/10.4236/jct.2016.79064
    連結:
  7. Holecek, M. (2013). Side effects of long-term glutamine supplementation. Journal of Parenteral and Enteral Nutrition, 37(5), 607–616. https://doi.org/10.1177/0148607112460682
    連結:
  8. Liang, S. L., Carlson, G. C., & Coulter, D. A. (2006). Dynamic regulation of synaptic GABA release by the glutamate-glutamine cycle in hippocampal area CA1. The Journal of Neuroscience, 26(33), 8537–8548. https://doi.org/10.1523/JNEUROSCI.0329-06.2006
    連結:
  9. Loven, D., Levavi, H., Sabach, G., Zart, R., Andras, M., Fishman, A., ... Gadoth, N. (2009). Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. European Jounral of Cancer Care, 18(1), 78–83. https://doi.org/10.1111/j.1365-2354.2008.00996.x
    連結:
  10. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed1000097
    連結:
  11. Oxford Centre. (n.d.). Critical appraisal skills programme (CASP). Retrieved from http://www.casp-uk.net/
    連結:
  12. Schloss, J. M., Colosimo, M., Airey, C., Masci, P. P., Linnane, A. W., & Vitetta, L. (2013). Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review. Clinical Nutrition, 32(6), 888–893. https://doi.org/10.1016/j.clnu.2013.04.007
    連結:
  13. Strasser, F., Demmer, R., Böhme, C., Schmitz, S. F., Thuerlimann, B., Cerny, T., & Gillessen, S. (2008). Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: A randomized, placebo-controlled, double-blind study. The Oncologist, 13(3), 337–346. https://doi.org/10.1634/theoncologist.2007-0217
    連結:
  14. Stubblefield, M. D., Vahdat, L. T., Balmaceda, C. M., Troxel, A. B., Hesdorffer, C. S., & Gooch, C. L. (2005). Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clinical Oncology, 17(4), 271–276. https://doi.org/10.1016/j.clon.2004.11.014
    連結:
  15. Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., & Hart, C. (2007). Putting evidence into practice®: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 11(6), 901–913. https://doi.org/10.1188/07.CJON.901-913
    連結:
  16. Wang, W. S., Lin, J. K., Lin, T. C., Chen, W. S., Jiang, J. K., Wang, H. S., ... Chen, P. M. (2007). Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist, 12(3), 312–319. https://doi.org/10.1634/theoncologist.12-3-312
    連結:
  17. Mayans, L., & Mayans, D. (2015). Causes of peripheral neuropathy: Diabetes and beyond. The Journal of Family Practice, 64(12), 774–783.
  18. OCEBM Levels of Evidence Working Group. (n.d.). The Oxford 2011 levels of evidence. Retrieved from http://www.cebm.net/index.aspx?o=5653
  19. Vahdat, L., Papadopoulos, K., Lange, D., Leuin, S., Kaufman, E., Donovan, D., ... Balmaceda, C. (2001). Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical Cancer Research, 7(5), 1192–1197.